CompaniesBukwang Pharmaceutical

Bukwang Pharmaceutical

active

Seoul, Korea

Founded 1960

Website

About

OTC Products

Areas of Focus

Categories

Generic Drug

Clinical Trials (39)

View all

Total Trials

As Lead Sponsor

As Collaborator

Total Enrollment

3,365

By Phase

PHASE1: 5PHASE2: 10PHASE3: 8PHASE4: 13PHASE1/PHASE2: 1

By Status

COMPLETED: 27TERMINATED: 11UNKNOWN: 1

Clinical Trials Pipeline39 trials

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Phase 1/2

Phase 2/3

N/A

Phase

Status

Role

Condition

2001

2002

2003

2004

2005

2006

2007

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

2024

2025

2026

Today

NCT00305019

Safety and Antiviral Activity of Clevudine in Patients Infected With Hepatitis B Virus

Phase: Phase 2

Role: Lead Sponsor

Start: Jul 31, 2002

Completion: Mar 31, 2004

NCT00313261

Safety and Efficacy Study of L-FMAU in Chronic HBV Patients of L-FMAU-201 Placebo Group

Phase: Phase 2

Role: Lead Sponsor

Start: Jun 30, 2003

Completion: Feb 28, 2005

NCT00313287

Safety and Antiviral Activity Study of Clevudine 30 mg QD in Patient With Chronic HBV

Phase: Phase 3

Role: Lead Sponsor

Start: Jun 30, 2003

Completion: Nov 30, 2004

NCT00313274

Safety and Antiviral Activity Study of Clevudine 30 mg QD in Patients With HBeAg(-) Chronic HBV

Phase: Phase 3

Role: Lead Sponsor

Start: Jul 31, 2003

Completion: Dec 31, 2004

NCT00362700

Safety and Efficacy Study of Retreated Clevudine in Chronic HBV Patients Who Received Clevudine in L-FMAU-201

Phase: Phase 2

Role: Lead Sponsor

Start: Jul 31, 2003

Completion: Oct 31, 2005

NCT00362505

Safety and Antiviral Activity of Clevudine in Patients Who Have Completed the L-FMAU-301 or L-FMAU-302 Trials

Phase: Phase 3

Role: Lead Sponsor

Start: Jun 30, 2004

Completion: Mar 31, 2006

NCT00362674

Durability of Antiviral Activity in Chronic HBV Patients Who Showed Complete Response in L-FMAU-301,302 or 303 Trial

Phase: N/A

Role: Lead Sponsor

Start: Jun 30, 2005

Completion: Not specified

NCT00362674

NCT00362635

Compare the Efficacy and Safety of 48-week Treatment With Clevudine 30mg Versus Lamivudine 100mg for CHB Infection

Phase: Phase 3

Role: Lead Sponsor

Start: Aug 31, 2006

Completion: Not specified

NCT00362635

NCT00501124

Safety and Efficacy Study of Clevudine Compared With Clevudine and Vaccine in Patient With HBeAg(+) Chronic HBV

Phase: Phase 4

Role: Lead Sponsor

Start: May 31, 2007

Completion: Not specified

NCT00501124

NCT00558818

Long-term Study With Clevudine

Phase: Phase 4

Role: Lead Sponsor

Start: Jun 30, 2007

Completion: Sep 30, 2011

NCT00558818

NCT00558493

Switching Study From Lamivudine to Clevudine in the Chronic Hepatitis B Patients

Phase: Phase 4

Role: Lead Sponsor

Start: Nov 30, 2007

Completion: Not specified

NCT00558493

NCT00672867

A Pilot Study to Evaluate the Safety and Efficacy of Clevudine or Adefovir Patients With LC-B

Phase: Phase 3

Role: Lead Sponsor

Start: Dec 31, 2007

Completion: Sep 30, 2014

NCT00672867

NCT00641082

A Double-Blind Randomized Clinical Trial Comparing the Safety and Antiviral Activity of 48-week Clevudine and Adefovir Dipivoxil in HBeAg(-) Chronic Hepatitis B With Compensated Liver Function

Phase: Phase 4

Role: Lead Sponsor

Start: Feb 29, 2008

Completion: Not specified

NCT00641082

NCT01264367

A Study to Evaluate the Efficacy and Safety of Clevudine and Peg-interferon in Sequence Compared With Clevudine Alone in the Patients With HBeAg(+) Chronic Hepatitis B or Clevudine and Peg-interferon Sequential Treatment in Patients With Chronic Hepatitis B Who Have HBeAg(+)

Phase: Phase 4

Role: Lead Sponsor

Start: Dec 31, 2008

Completion: May 31, 2014

NCT01264367

NCT00798460

Efficacy of Clevudine Plus Lamivudine for Lamivudine-resistant Chronic Hepatitis B Patients

Phase: Phase 4

Role: Collaborator

Start: Dec 31, 2008

Completion: Nov 30, 2010

NCT01264107

An Open Study to Evaluate the Sustained Effect in Patients Showing Virological Responses With Muscle-related Symptom of Chronic Hepatitis B Patients Who Received Clevudine

Phase: N/A

Role: Lead Sponsor

Start: Apr 30, 2009

Completion: Apr 30, 2012

NCT01258699

A Study Comparing the Pharmacokinetics of BK-C-0701 320mg, 480mg and Thiocacid HR Tab 600mg in Healthy Adult Male Subjects

Phase: Phase 1

Role: Lead Sponsor

Start: Aug 31, 2009

Completion: Not specified

NCT01258699

NCT01266005

A Study to Compare and Evaluate Intrahepatic cccDNA Reduction After Administrating Clevudine or Entecavir in the Chronic HBV Patients

Phase: Phase 4

Role: Lead Sponsor

Start: Aug 31, 2009

Completion: Jan 31, 2014

NCT01266005

NCT01264133

A Study With Clevudine Monotherapy or Adefovir and Clevudine Combination in Patients With Chronic Hepatitis B

Phase: Phase 4

Role: Lead Sponsor

Start: Sep 30, 2009

Completion: Dec 31, 2014

NCT01264133

NCT01264094

A Study to Evaluate the Efficacy and the Change of sAg Levels in Chronic Hepatitis B Patients Receiving Clevudine Treatment Over the Long Period

Phase: Phase 4

Role: Lead Sponsor

Start: Nov 30, 2009

Completion: Jun 30, 2015

NCT01264094

NCT01264354

An Open Study to Evaluate the Efficacy, Safety of Clevudine Monotherapy or Adefovir and Clevudine Combination in Patients With Chronic Hepatitis B

Phase: Phase 4

Role: Lead Sponsor

Start: Mar 31, 2010

Completion: Feb 28, 2013

NCT01263002

A Study With Clevudine Monotherapy or Adefovir and Clevudine Combination in Proportion to Roadmap Concept in Patients With HBV Associated-HCC

Phase: Phase 4

Role: Lead Sponsor

Start: Jun 30, 2010

Completion: Sep 30, 2013

NCT01261143

Randomized, Double-blind Study to Assess the Efficacy and Safety of α-lipoic Acid Versus BK-C-0701 in Subjects With Diabetic Neuropathy

Phase: Phase 3

Role: Lead Sponsor

Start: Aug 31, 2010

Completion: Not specified

NCT01261143

NCT01258686

Clinical Study With Silymarin in the Patients With Chronic Hepatitis C Infection Who Failed Conventional Antiviral Therapy

Phase: Phase 3

Role: Lead Sponsor

Start: Nov 30, 2010

Completion: Aug 31, 2013

NCT01507922

Comparative Efficacy and Safety of Fenoverine

Phase: Phase 4

Role: Lead Sponsor

Start: Dec 31, 2011

Completion: Jun 30, 2013

NCT01581242

A Clinical Trial to Investigate the Pharmacokinetic Drug-drug Interaction of Clevudine and Adefovir Dipivoxil After Oral Administration in Healthy Male Subjects

Phase: Phase 1

Role: Lead Sponsor

Start: Apr 30, 2012

Completion: Not specified

NCT01581242

NCT01624779

Intrathecal Transplantation Of Autologous Adipose Tissue Derived MSC in the Patients With Spinal Cord Injury

Phase: Phase 1

Role: Lead Sponsor

Start: Apr 30, 2012

Completion: May 31, 2014

NCT01497704

Dose-Escalation and Safety Trial of YN968D1

Phase: Phase 1/2

Role: Collaborator

Start: Apr 30, 2012

Completion: May 31, 2015

NCT03552991

Effects of Dietary Fiber on Glucose Control in Subjects With Type 2 Diabetes Mellitus

Phase: Phase 4

Role: Collaborator

Start: Feb 28, 2014

Completion: May 31, 2018

NCT03552991

NCT02317796

Adult Subjects With Uncontrolled Type 2 Diabetes

Phase: Phase 2

Role: Collaborator

Start: Dec 31, 2014

Completion: Feb 29, 2016

NCT02439203

Efficacy and Safety of JM-010 in PD With Levodopa-Induced Dyskinesia

Phase: Phase 2

Role: Lead Sponsor

Start: May 31, 2015

Completion: Jan 31, 2016

NCT02711969

A Study of Apatinib Mesylate (YN968D1) 1,000mg in Gastric Cancer Patient Failed to Standard Treatment

Phase: Phase 1

Role: Lead Sponsor

Start: Mar 31, 2016

Completion: Mar 31, 2019

NCT03279263

An Add-on Study of MLR-1023 in Adults With Uncontrolled Type 2 Diabetes on Metformin Therapy

Phase: Phase 2

Role: Collaborator

Start: Sep 1, 2017

Completion: Sep 30, 2019

NCT03465787

A 6-week Study to Evaluate the Efficacy and Safety of Lurasidone HCL in Acutely Psychotic Patients With Schizophrenia

Phase: Phase 3

Role: Lead Sponsor

Start: Apr 9, 2018

Completion: Oct 26, 2022

NCT03465787

NCT03956979

A Study in Parkinson's Disease in Patients With Moderate to Severe Dyskinesia

Phase: Phase 2

Role: Collaborator

Start: Jul 22, 2019

Completion: Mar 21, 2024

NCT03956979

NCT04347915

The Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Moderate COVID-19

Phase: Phase 2

Role: Lead Sponsor

Start: May 26, 2020

Completion: Feb 26, 2021

NCT04891302

The Proof of Concept Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Mild and Moderate COVID-19

Phase: Phase 2

Role: Lead Sponsor

Start: Mar 19, 2021

Completion: Jul 8, 2021

NCT04377945

Study in Parkinson's Disease Patients With Dyskinesia With Combinations of JM-010 and Its Individual Components

Phase: Phase 2

Role: Lead Sponsor

Start: Apr 28, 2021

Completion: Feb 14, 2024

NCT06014853

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SOL-804 in Healthy Male Subjects

Phase: Phase 1

Role: Lead Sponsor

Start: Aug 10, 2023

Completion: Nov 16, 2023

Hover over trial bars to see details

Recent Trials

NCT06014853Lead Sponsor

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SOL-804 in Healthy Male Subjects

PHASE1Completed

48 participants

Started: Aug 10, 2023 · Completed: Nov 16, 2023

NCT04377945Lead Sponsor

Study in Parkinson's Disease Patients With Dyskinesia With Combinations of JM-010 and Its Individual Components

PHASE2Terminated

41 participants

Started: Apr 28, 2021 · Completed: Feb 14, 2024

NCT04891302Lead Sponsor

The Proof of Concept Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Mild and Moderate COVID-19

PHASE2Completed

104 participants

Started: Mar 19, 2021 · Completed: Jul 8, 2021

NCT04347915Lead Sponsor

The Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Moderate COVID-19

PHASE2Completed

64 participants

Started: May 26, 2020 · Completed: Feb 26, 2021

NCT03956979Collaborator

A Study in Parkinson's Disease in Patients With Moderate to Severe Dyskinesia

PHASE2Completed

89 participants

Started: Jul 22, 2019 · Completed: Mar 21, 2024

View all 39 trials →

Locations (1)

Headquarters

Seoul, Korea

Map

Loading map...